COMMUNIQUÉS West-GlobeNewswire

Barinthus Bio Reports First Quarter 2026 Financial Results and Updates on Corporate Developments
30/04/2026
Proposed combination with Clywedog Therapeutics Inc. (“Clywedog”) progressing towards closing which will result in a differentiated company focusing on metabolic and autoimmune pipeline assets with multiple important [...]
Alterity Therapeutics Releases Appendix 4C – Q3 FY26 Quarterly Cash Flow Report & Corporate Update
30/04/2026
Highlights Aligned with the FDA in two Positive Type C meetings supporting key elements of the planned Phase 3 program for ATH434 in MSA Advancing ATH434 toward pivotal Phase 3 program; on track for End-of-Phase 2 FDA [...]
uniQure Announces Successful UK MHRA Pre-Submission Meeting for AMT-130 in Huntington’s Disease
30/04/2026
~ Submission of a UK Marketing Authorization Application for AMT-130 is expected in the third quarter of 2026 ~ ~ Type B Meeting with U.S. FDA granted in second quarter; expect to discuss potential Phase III design and [...]
SweetWater Brewing Company and Salt Life Launch Livin’ Salty: The Ultimate Summer Craft Brew Collaboration
30/04/2026
Introducing Livin’ Salty: Your Go-To Lager for Sun, Sand, and Summer Fun ATLANTA, April 30, 2026 (GLOBE NEWSWIRE) -- SweetWater Brewing Company (“SweetWater Brewing” or “SweetWater”), the leading craft beer brand in the [...]
Verano Announces Strong First Quarter 2026 Financial Results Highlighted by $208 Million in Revenue
30/04/2026
Company generates revenue growth for second consecutive quarter driven by retail performance and announces $20 million share repurchase authorization CHICAGO, April 30, 2026 (GLOBE NEWSWIRE) -- Verano Holdings Corp. ( [...]
Aclarion Delivers Strong Q1 2026 Results with 196% Annual Scan Volume Growth Reflecting Accelerating Clinical Adoption
30/04/2026
Triple-digit annual growth signals accelerating Nociscan adoption and integration into clinical workflows Advancing reimbursement and clinical milestones, with CLARITY trial interim readout anticipated in Q4 2026 [...]
LENSAR® to Report First Quarter 2026 Results on May 8, 2026
30/04/2026
ORLANDO, Fla., April 30, 2026 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, [...]
Novartis finalizes US manufacturing and R&D expansion plan with seventh new facility
30/04/2026
At one-year mark, company has progressed all components of US investment plan to support delivery of innovative medicines to US patients New active pharmaceutical ingredients facility in North Carolina to enable end‑to‑ [...]
Aptose Biosciences Announces Update on Anticipated Timing of Closing of the Plan of Arrangement with Hanmi Pharmaceutical
30/04/2026
SAN DIEGO and TORONTO, April 30, 2026 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“ Aptose ” or the “ Company ”) (TSX: APS; OTC: APTOF) announced today that closing of the previously announced arrangement (the “ [...]
Indivior Reports First Quarter 2026 Financial Results and Raises Full-Year 2026 Guidance
30/04/2026
Q1’26 Total Net Revenue of $317 Million, Up 19% YoY Q1’26 Total SUBLOCADE® Net Revenue of $232 Million, Up 32% YoY Q1'26 GAAP Net Income of $89 Million and Q1'26 Non-GAAP Net Income of $123 Million Record Quarterly [...]
Medicenna and Fondazione Melanoma Onlus Announce Presentation on NEOCYT Trial at ASCO 2026
30/04/2026
NEO-CYT is a randomized, multi-centre trial of neoadjuvant MDNA11 (before curative intent surgery) sponsored by the Fondazione Melanoma Onlus, and led by Professor Paolo A. Ascierto of the Istituto Nazionale Tumori [...]
Novartis finalizes US manufacturing and R&D expansion plan with seventh new facility
30/04/2026
At one-year mark, company has progressed all components of US investment plan to support delivery of innovative medicines to US patients New active pharmaceutical ingredients facility in North Carolina to enable end‑to‑ [...]
Cartesian Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
30/04/2026
Enrollment continues to progress in Phase 3 AURORA trial of Descartes-08 in myasthenia gravis Phase 2 TRITON trial of Descartes-08 in dermatomyositis and antisynthetase syndrome initiated Multiple patients enrolled in [...]
TG Therapeutics to Host Conference Call on First Quarter 2026 Financial Results and Business Update
30/04/2026
Conference Call to be Held Wednesday, May 6, 2026, at 8:30 am ET NEW YORK, April 30, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held, Wednesday, May 6, [...]
Northwestern Medicine Opens $15 Million Center Expanding Advanced Gastrointestinal Care to Suburban Chicago
30/04/2026
The Center for Advanced Endoscopy offers some of the most advanced endoscopic procedures available in the United States WINFIELD, Ill., April 30, 2026 (GLOBE NEWSWIRE) -- Northwestern Medicine is expanding access to [...]
Vireo Growth to Acquire FLUENT in All-Stock Transaction
30/04/2026
MINNEAPOLIS and TAMPA, Fla., April 30, 2026 (GLOBE NEWSWIRE) -- Vireo Growth Inc. (CSE: VREO) (OTCQX: VREOF) (“Vireo”), a multi-state cannabis operator, and FLUENT Corp. (CSE: FNT.U) (OTCQB: CNTMF) (“FLUENT” or the “ [...]
AC Immune First Quarter 2026 Financial and Corporate Updates
30/04/2026
AC Immune First Quarter 2026 Financial and Corporate Updates Dosed first subjects in Phase 1 trial of brain-penetrant small molecule NLRP3 inhibitor ACI-19764 with SAD/MAD results in healthy volunteers expected in H2 [...]
Axogen, Inc. to Participate in the 2026 Bank of America Global Healthcare Conference
30/04/2026
ALACHUA, Fla. and TAMPA, Fla., April 30, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, [...]
AC Immune Initiates Final Cohort in Ongoing Phase 1b/2 ABATE Trial of Anti-Abeta Active Immunotherapy to Treat Alzheimer's Disease
30/04/2026
AC Immune Initiates Final Cohort in Ongoing Phase 1b/2 ABATE Trial of Anti-Abeta Active Immunotherapy to Treat Alzheimer's Disease Treatment of first patient in Cohort AD4 in ABATE trial triggers $12 million milestone [...]

Pages